RetinalGeniX™ Technologies Inc. Contracts With MEDsan, Inc. to Provide Diagnostic Testing Services for Its Institutional Review Board to Conduct a Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration RETINALGENIX AND MEDSAN CONTRACT TO ADVANCE STUDY INTENDED TO PERSONALIZE MEDICAL EVALUATIONS FOR PATIENTS RECEIVING TREATMENT FOR WET MACULAR DEGENERATION

Vitrectomy Devices Market Size ($2,003.24Mn by 2028) Lead by Vitrectomy Machines (6.5% CAGR) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com New York, Nov. 29, 2021 (GLOBE NEWSWIRE) -- According to our new research study on Vitrectomy Devices Market Size, Share, Revenue, Growth, Trends, Forecast to 2028 - COVID-19 Impact and Global...

Clearside Biomedical, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Zuprata™ in Diabetic Macular Edema ALPHARETTA, Ga., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat...

Foundation Fighting Blindness Clinical Research Institute to Launch Natural History Study for Stargardt Disease to Help Prepare for Clinical Trials COLUMBIA, Md., March 13, 2013 (GLOBE NEWSWIRE) -- The Foundation Fighting Blindness Clinical Research Institute is launching a natural history study of people affected by Stargardt disease, a genetic...